Holen Sie sich die Stockscreener-App
3.98
4.19%
0.16
Handel nachbörslich:
3.97
-0.010
-0.25%
Schlusskurs vom Vortag:
$3.82
Offen:
$3.83
24-Stunden-Volumen:
724.31K
Relative Volume:
0.88
Marktkapitalisierung:
$345.55M
Einnahmen:
$380.79M
Nettoeinkommen (Verlust:
$49.27M
KGV:
5.6857
EPS:
0.7
Netto-Cashflow:
$10.68M
1W Leistung:
+14.04%
1M Leistung:
+6.13%
6M Leistung:
+1.53%
1J Leistung:
+99.00%
1-Tages-Spanne:
$3.80
$4.12
1-Wochen-Bereich:
$3.42
$4.12
52-Wochen-Spanne:
$1.575
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Branche
Telefon
617-683-0917
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Vergleichen Sie AMLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
3.98 | 345.55M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - markets.businessinsider.com
Q1 Earnings Forecast for AMLX Issued By Leerink Partnrs - Defense World
Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - markets.businessinsider.com
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by American Century Companies Inc. - Defense World
American Century Companies Inc. Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - The AM Reporter
Wellington Management Group LLP Acquires Shares of 209,708 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - The AM Reporter
Wellington Management Group LLP Makes New $793,000 Investment in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Amylyx upgraded at Mizuho on potential of lead asset - MSN
First subject dosed in Amylyx’s Phase I trial of ALS therapy - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis - BioSpace
Amylyx Pharma Announces First Participant Dosed In Phase 1, Multiple Ascending Dose Lumina Trial Of Amx0114 In People Living With Amyotrophic Lateral Sclerosis - marketscreener.com
Breakthrough ALS Treatment Enters Human Trials: Amylyx Targets New Disease Mechanism - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Is Now The Time To Buy Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Stock? - stocksregister.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Rating Increased to Outperform at Mizuho - Defense World
Mizuho Upgrades Amylyx Pharmaceuticals (AMLX) - Nasdaq
Amylyx stock upgraded at Mizuho on lead asset (AMLX:NASDAQ) - Seeking Alpha
Mizuho lifts Amylyx stock rating, doubles price target to $7 - Investing.com
Mizuho lifts Amylyx stock rating, doubles price target to $7 By Investing.com - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - markets.businessinsider.com
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Don't Ignore The Insider Selling In Amylyx Pharmaceuticals - simplywall.st
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Amylyx Pharmaceuticals co-CEO Justin Klee sells $74,454 in stock - Investing.com Australia
Optimistic Investors Push Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Up 26% But Growth Is Lacking - simplywall.st
Amylyx Pharmaceuticals Executives Unload Massive Stock Shares! - TipRanks
Amylyx Pharmaceuticals co-CEO Justin Klee sells $74,454 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals chief medical officer sells $43,082 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals chief medical officer sells $43,082 in stock - Investing.com
Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals’ co-CEO Joshua Cohen sells $74,482 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals Executives Sell Shares to Cover Tax Obligations - TradingView
Amylyx Pharmaceuticals chief legal officer sells $31,954 in stock - Investing.com India
Amylyx Pharmaceuticals’ co-CEO Joshua Cohen sells $74,482 in stock - Investing.com
Amylyx Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Amylyx Pharmaceuticals Set to Reveal Latest Corporate Strategy at Major Healthcare Conference - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - markets.businessinsider.com
Does Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Still Look Hot This Week? - stocksregister.com
Charles Schwab Investment Management Inc. Lowers Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - markets.businessinsider.com
Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out - Markets Insider
Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5? - Insider Monkey
Amylyx Pharmaceuticals director Bernhardt Zeiher buys $37,005 in stock By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals director Bernhardt Zeiher buys $37,005 in stock - Investing.com India
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):